Silence Therapeutics Revenue vs. Price To Sales
| SLN Stock | USD 7.92 0.25 3.26% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 25.4 M | Current Value 26.6 M | Quarterly Volatility 9.6 M |
For Silence Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Silence Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Silence Therapeutics PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Silence Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Silence Therapeutics PLC over time as well as its relative position and ranking within its peers.
Silence |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Silence Therapeutics PLC Price To Sales vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Silence Therapeutics's current stock value. Our valuation model uses many indicators to compare Silence Therapeutics value to that of its competitors to determine the firm's financial worth. Silence Therapeutics PLC is currently regarded number one company in revenue category among its peers. It is rated third in price to sales category among its peers . The ratio of Revenue to Price To Sales for Silence Therapeutics PLC is about 1,254,325 . At this time, Silence Therapeutics' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Silence Therapeutics' earnings, one of the primary drivers of an investment's value.Silence Revenue vs. Competition
Silence Therapeutics PLC is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 39.7 Million. Silence Therapeutics totals roughly 25.38 Million in revenue claiming about 64% of equities under Health Care industry.
Silence Price To Sales vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Silence Therapeutics |
| = | 25.38 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Silence Therapeutics |
| = | 20.23 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Silence Price To Sales Comparison
Silence Therapeutics is currently under evaluation in price to sales category among its peers.
Silence Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Silence Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Silence Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Silence Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Silence Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 64.3 M | 57.1 M | |
| Operating Income | -49.6 M | -47.1 M | |
| Income Before Tax | -50.3 M | -47.8 M | |
| Total Other Income Expense Net | -706 K | -670.7 K | |
| Net Loss | -50.3 M | -47.8 M | |
| Income Tax Expense | -7 M | -6.7 M | |
| Net Interest Income | 1.4 M | 1.5 M | |
| Interest Income | 1.4 M | 1.5 M | |
| Net Loss | -43.3 M | -41.1 M | |
| Net Loss | -36.4 M | -38.3 M | |
| Change To Netincome | 3.2 M | 3.4 M | |
| Net Loss | (1.17) | (1.22) | |
| Income Quality | 0.78 | 0.86 | |
| Net Income Per E B T | 0.86 | 0.97 |
Silence Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Silence Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Silence Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Silence Therapeutics' important profitability drivers and their relationship over time.
Use Silence Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Silence Therapeutics Pair Trading
Silence Therapeutics PLC Pair Trading Analysis
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Silence Therapeutics position
In addition to having Silence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trump Equities Thematic Idea Now
Trump Equities
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project Silence Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Silence Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Silence Therapeutics' income statement, its balance sheet, and the statement of cash flows.